Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

9 Jan 2020 07:00

RNS Number : 1997Z
InnovaDerma PLC
09 January 2020
 

LEI: 213800WRAP6W8VDL6B38

InnovaDerma PLC

("InnovaDerma" or the "Company")

Trading Statement

InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life sciences products, provides a trading update for the six months ended 31 December 2019.

The Company generated revenues of £5.0m, up c.28% compared to the same period last year (H1 2019: £3.9m). The increase in revenue was driven predominantly by Skinny Tan and its performance on the Company's DTC platform and in the UK retail channel. The former has continued to benefit from a revised digital engagement strategy and investment in all three key geographical markets: UK, US and Australia. Product innovation remains key to the business and the first six months included the launch of the limited-edition Choc range in Superdrug, which resulted in exceptional demand and the continued success of Wonder Serum in Boots has provided a strong platform for the season ahead. These initiatives have alleviated the effects of a softer UK high street retail environment and shelf space rationalisation, typical of seasonal products such as Skinny Tan.

The UK DTC channel accounted for 56% of total revenue (H1 2019: 59%). Skinny Tan DTC revenue was supported by Black Friday and Christmas promotions, up c.27% compared to the same period last year. UK retail revenue was almost double that of H1 2019, driven by the Skinny Tan rollout into Boots' stores, an opening order from Tesco, and continued support from Superdrug. Pleasingly, our core brand also made excellent progress in Australia and the US DTC markets, with the introduction of new products. Whilst these two territories remain a small proportion of our overall revenue, growth was robust.

Roots revenues were lower than expected due to competitive shelf positioning, however, new products, particularly Platinum Colour Protect, performed well. Charles + Lee continued to build momentum with Australian retailers and almost doubled revenues compared to last year.

Life Sciences' revenue increased by 71% on the previous year as a result of DTC sales driven by online 'influencers', predominantly in the US.

As in previous years, the Company expects revenue and profit growth to be strongly weighted to H2 FY2020, reflecting the peak tanning season. Skinny Tan remains well positioned to perform well in the UK despite a challenging outlook for the UK retail market. Charles & Lee is growing in popularity, and we look forward to expanding its geographical spread. Roots will receive extra marketing and product development focus to expand its customer base and product offering in 2020.

The momentum of the first half coupled with our forthcoming new category launch give us much confidence for the full year. The balance sheet remains healthy and with an increased retail footprint coupled with continued focus on our DTC channels in core regions, the Company expects to generate strong revenue and profit growth in the second half of the year.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

InnovaDerma

Joe Bayer

Kieran Callan c/o TB Cardew

www.innovaderma.com

 

 

+61 (0)3 9863 8030

+44 (0)20 7930 0777

finnCap Ltd

Geoff Nash/ Kate Bannatyne

Alice Lane/Manasa Patil - Corporate Broking

 

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser

 

+ 44 (0)20 7930 0777

innovaDerma@tbcardew.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKFBNPBKDCDK
Date   Source Headline
15th Feb 202112:22 pmBUSForm 8.3 - INNOVADERMA PLC
12th Feb 20216:25 pmRNSForm 8.3 - Innovaderma PLC
12th Feb 20214:43 pmRNSForm 8.3 - [InnovaDerma plc]
12th Feb 20214:40 pmRNSForm 8.3 - [InnovaDerma plc]
12th Feb 20212:35 pmRNSForm 8.3 - Creightons
11th Feb 202111:50 amRNSForm 8.3 - Innovaderma plc
10th Feb 202111:25 amRNSForm 8.3 - Innovaderma plc
10th Feb 202111:03 amRNSForm 8.3 - Innovaderma PLC
9th Feb 20211:18 pmBUSForm 8.3 - INNOVADERMA PLC
5th Feb 20215:14 pmRNSForm 8.3 - Innovaderma Plc
4th Feb 20215:37 pmRNSForm 8 (OPD) CREIGHTONS
4th Feb 20213:31 pmRNSForm 8 (OPD) InnovaDerma PLC
3rd Feb 202112:27 pmBUSForm 8.3 - Innovaderma Plc
2nd Feb 20214:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20214:35 pmRNSPrice Monitoring Extension
2nd Feb 20214:12 pmGNWForm 8.3 - [InnovaDerma plc]
2nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
2nd Feb 20212:00 pmRNSPrice Monitoring Extension
2nd Feb 202111:41 amRNSStatement re Possible Offer
2nd Feb 202111:05 amRNSSecond Price Monitoring Extn
2nd Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
28th Jan 202111:22 amRNSHolding(s) in Company
22nd Jan 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
20th Jan 20219:19 amRNSProposed Placing and Proposed Open Offer
18th Jan 202111:59 amRNSHolding(s) in Company
15th Jan 20214:41 pmRNSSecond Price Monitoring Extn
15th Jan 20214:35 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSLoan Agreement
11th Jan 20217:08 amRNSTrading Statement
16th Dec 202012:18 pmRNSResults of the AGM and GM and Directorate Change
2nd Dec 20207:00 amRNSDirectorate Change
24th Nov 20207:02 amRNSDirectorate Change
24th Nov 20207:00 amRNSNotice of General Meeting and adjournment of AGM
18th Nov 20207:00 amRNSDirectorate Change
11th Nov 202012:07 pmRNSAdjournment of AGM
29th Oct 20208:45 amRNSHolding(s) in Company
29th Oct 20208:28 amRNSDirector/PDMR Shareholding
27th Oct 20204:41 pmRNSSecond Price Monitoring Extn
27th Oct 20204:36 pmRNSPrice Monitoring Extension
27th Oct 20202:05 pmRNSSecond Price Monitoring Extn
27th Oct 20202:01 pmRNSPrice Monitoring Extension
23rd Oct 20202:05 pmRNSRequisition notice and Progress of CEO appointment
16th Oct 20204:32 pmRNSNotice of AGM
16th Oct 20209:21 amRNSAppointment of Non-executive Director
15th Oct 20204:40 pmRNSSecond Price Monitoring Extn
15th Oct 20204:35 pmRNSPrice Monitoring Extension
15th Oct 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.